CONFERENCE PROCEEDINGS
Advanced Search
Home > Proceedings > Volume 9709 > Article
Presentation
27 April 2016 Development of InCVAX as a novel in situ autologous vaccine for metastatic cancers (Conference Presentation)
Tomas Hode, Luciano Alleruzzo, Joseph Raker, Samuel Siu Kit Lam, Robert E. Nordquist, Wei R. Chen
Author Affiliations +
Proceedings Volume 9709, Biophotonics and Immune Responses XI; 97090I (2016) https://doi.org/10.1117/12.2216110
Event: SPIE BiOS, 2016, San Francisco, California, United States
Abstract
A novel method, an in situ autologous whole-cell cancer vaccine (inCVAX), is being developed by Immunophotonics, Inc., for the treatment of metastatic cancers. inCVAX combines phototherapy and immunotherapy to potentially induce a systemic anti-tumor immune response in the hosts. Immunophotonics and its academic partners have spent years conducting nonclinical research, developing CMC techniques and conducting clinical research. In 2015 the company initiated a late-stage (II/III) clinical trial in South America for advanced breast cancer patients. The process of developing the inCVAX approach from a laboratory setting into clinical trials requires significant efforts from a group of dedicated engineers, scientists, and physicians. The growth of the company and its business advances demonstrated the determination of a group of visionary investors, entrepreneurs, and business leaders. This talk will chronicle the milestones of the scientific achievement, medical progress, and business development of Immunophotonics.
Conference Presentation
© (2016) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Citation Download Citation
Tomas Hode, Luciano Alleruzzo, Joseph Raker, Samuel Siu Kit Lam, Robert E. Nordquist, and Wei R. Chen "Development of InCVAX as a novel in situ autologous vaccine for metastatic cancers (Conference Presentation)", Proc. SPIE 9709, Biophotonics and Immune Responses XI, 97090I (27 April 2016); https://doi.org/10.1117/12.2216110
ACCESS THE FULL ARTICLE
ORGANIZATIONAL
Sign in with credentials provided by your organization.
INSTITUTIONAL
Select your institution to access the SPIE Digital Library.
SELECT YOUR INSTITUTION
PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
PERSONAL SIGN IN
No SPIE Account? Create one
PURCHASE THIS CONTENT
SUBSCRIBE TO DIGITAL LIBRARY
50 downloads per 1-year subscription
Members: $195
Non-members: $335 ADD TO CART
25 downloads per 1 - year subscription
Members: $145
Non-members: $250 ADD TO CART
PURCHASE SINGLE ARTICLE
Includes PDF, HTML & Video, when available
Members: $17.00
Non-members: $21.00 ADD TO CART
PROCEEDINGS
 PRESENTATION
WATCH
PRESENTATION SAVE TO MY LIBRARY
GET CITATION
Advertisement
Advertisement
KEYWORDS
Cancer
Oncology
Clinical trials
Breast cancer
Clinical research
Phototherapy
Biomedical optics
RELATED CONTENT
Subscribe to Digital Library
Receive Erratum Email Alert
Back to Top